Irene Sargiannidou

6 Iroon Avenue
Nicosia, 2371, Cyprus

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

A dose-escalation and safety gene therapy study in a model of CMT4C neuropathy.

A dose-escalation and safety gene therapy study in a model of CMT4C neuropathy.

Journal: Gene therapy

Published: December 11, 2025

Developing a gene therapy for Charcot-Marie-Tooth disease: progress and challenges.

Developing a gene therapy for Charcot-Marie-Tooth disease: progress and challenges.

Journal: Regenerative medicine

Published: April 12, 2025

A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X.

A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 08, 2024

Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.

Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: July 31, 2024

Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer's Disease.

Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer's Disease.

Journal: Life (Basel, Switzerland)

Published: March 10, 2023

Charcot-Marie-Tooth neuropathies: Current gene therapy advances and the route toward translation.

Charcot-Marie-Tooth neuropathies: Current gene therapy advances and the route toward translation.

Journal: Journal of the peripheral nervous system : JPNS

Published: February 21, 2023

AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C.

AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: February 14, 2023

Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro.

Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro.

Journal: Journal of the peripheral nervous system : JPNS

Published: February 06, 2023

Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.

Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy.

Journal: Molecular therapy. Methods & clinical development

Published: January 03, 2023

Glial Gap Junction Pathology in the Spinal Cord of the 5xFAD Mouse Model of Early-Onset Alzheimer's Disease.

Glial Gap Junction Pathology in the Spinal Cord of the 5xFAD Mouse Model of Early-Onset Alzheimer's Disease.

Journal: International journal of molecular sciences

Published: November 01, 2022

Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A.

Aberrant Mitochondrial Dynamics and Exacerbated Response to Neuroinflammation in a Novel Mouse Model of CMT2A.

Journal: International journal of molecular sciences

Published: September 13, 2021

Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery.

Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery.

Journal: Scientific reports

Published: July 19, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026